Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
The ALIOS diet in male and female rodents recapitulates the clinical and transcriptomic features of NAFLD and NASH.
Journal article
Harris SE. et al, (2020), Am J Physiol Gastrointest Liver Physiol
-
Fighting liver fat.
Journal article
Koeckerling D. et al, (2020), Endocr Connect
-
Guidance for the prevention and emergency management of adult patients with adrenal insufficiency
Journal article
Simpson H. et al, (2020), Clinical medicine (London, England), 20, 371 - 378
-
The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1
Journal article
Barnard L. et al, (2020), The Journal of Steroid Biochemistry and Molecular Biology, 105724 - 105724
-
Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids
Journal article
Othonos N. et al, (2020), The Journal of Clinical Endocrinology & Metabolism